Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Iglu pastilles sugar free
120303000BBCAA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | 29 |
|
Buttercup Bronchostop Cough pastilles
120303000BBBYAI
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | 2 |
|
Echinaforce throat spray
120303000BBBXA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
|
Kilkof lozenges
120303000BBBZA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
|
Sinotar tablets
120303000BBBMA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
|
Throaties Blackcurrant pastilles
120303000BBBUA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
|
Throaties Strong Original pastilles
120303000BBBVA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
|
Zubes Honey & Lemon lozenges
120303000BBBWA0
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
|
Zubes Original lozenges
120303000BBBQAH
|
Proprietary compound preparation BNF 1203030 | Other lozenge and spray preparations | Ear, Nose and Oropharynx | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.